A comparison of front-line oral anticoagulants for the treatment of non-valvular atrial fibrillation: Effectiveness and safety of direct oral anticoagulants in the FANTASIIA registry
We present in this manuscript original data analysis from FANTASIIA population as well as data obtained through a search of PubMed for the clinical trials comparing DOAC in the main randomized trials of each DOAC and observational data of the real-world effects of DOACs compared to VKAs.EXPERT OPINION: In the absence of randomized, controlled head-to-head comparisons between DOACs, high-quality observational data can provide useful information on the comparative effectiveness of DOACs. Current clinical guidelines recommend the management of oral anticoagulation in AF patients with DOACs over VKA for stroke prevention; however, many guidelines generally do not suggest a specific DOAC choice in clinical practice. The revised evidence in this manuscript and our real experience reflects that apixaban and dabigatran show the best efficacy and safety profile.PMID:35924672 | DOI:10.1080/14656566.2022.2109961
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Authors: Mar ía Asunción Esteve-Pastor Jos é Miguel Rivera-Caravaca Mart ín Ruiz-Ortiz Javier Mu ñiz Inmaculada Rold án-Rabadán D éborah Otero Raquel L ópez-Gálvez Ángel Cequier Vicente Bertomeu-Mart ínez Lina Badim ón Manuel Anguita Gregory Y H Lip F Source Type: research
More News: Atrial Fibrillation | Clinical Trials | Drugs & Pharmacology | Pradaxa | Stroke | Vitamin K | Vitamins